Table S1 RT-primer pairs used in this study. Found at: doi:10.1371/journal.pone.0010726.s009 (0.04 DOC) Table S2 COBRA primer pairs used in this study. Found at: doi:10.1371/journal.pone.0010726.s010 (0.03 DOC) MB MB Acknowledgments We thank Peter W. Andrews (University of Sheffield) for the original NT2 cells, Michael Hershfield (Duke University, Durham) for the SAHH References 1. von Wangenheim KH, Peterson HP (2008) The role of cell differentiation in controlling cell multiplication and cancer. J Cancer Res Clin Oncol 134: 725–741. 2. Capp JP (2005) Stochastic gene expression, disruption of tissue averaging effects and cancer as a disease of development. Bioessays 27: 1277–1285. 3. Sell S (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51: 1–28. 4. Degos L (1999) Differentiating agents in the treatment of leukemia. Leuk Res 14: 717–719. 5. Jaenisch R, Young R (2008) Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132: 567–582. 6. Pietersen AM, van Lohuizen M (2008) Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol 20: 201–207. 7. Fouse SD, Shen Y, Pellegrini M, Cole S, Meissner A, et al. (2008) Promoter CpG methylation contributes to ES cell gene regulation in parallel with oct4/ Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell 2: 160–169. 8. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K (2006) Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20: 1123–1136. 9. Sessa L, Breiling A, Lavorgna G, Silvestri L, Casari G, et al. (2007) Noncoding RNA synthesis and loss of Polycomb group repression accompanies the colinear activation of the human HOXA cluster. RNA 13: 223–239. 10. Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, et al. (2008) Lineage- specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30: 755–766. 11. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G (2007) Genome regulation by polycomb and trithorax proteins. Cell 128: 735–745. 12. Breiling A, Sessa L, Orlando V (2007) Biology of polycomb and trithorax group proteins. Int Rev Cytol 258: 83–136. 13. Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85–93. 14. Tan J, Yang X, Zhuang L, Jiang X, Chen W, et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063. 15. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, et al. (2008) Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3- deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733–2743. 16. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, et al. (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579–1588. 17. Puppe J, Drost R, Liu X, Joosse SA, Evers B, et al. (2009) BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 11: R63. 18. Glazer RI, Hartman KD, Knode MC, Richard MM, Chiang PK, et al. (1986) 3- Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 135: 688–694. 19. Hatse S, De Clercq E, Balzarini J (1999) Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem Pharmacol 58: 539–555. 20. Corey SJ, Minden MB, Barber DL, Kantarjian H, Wang JC, et al. (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7: 118–129. 21. Andrews PW (1984) Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol 103: 285–293. 22. Andrews PW (2002) From teratocarcinomas to embryonic stem cells. Philos Trans R Soc Lond B Biol Sci 357: 405–417. 23. Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C, et al. (1984) Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab Invest 50: 147–162. 24. Pal R, Ravindran G (2006) Assessment of pluripotency and multilineage differentiation potential of NTERA-2 cells as a model for studying human embryonic stem cells. Cell Prolif 39: 585–598. Drug-Induced Differentiation antibody, Wei Cui (Imperial College, London) for the phOCT4-EGFP plasmid and Kristian Helin (University of Copenhagen) for HOXA-specific RT-primer sequences. Author Contributions Conceived and designed the experiments: FL AB. Performed the experiments: TM YO AB. Analyzed the data: YO FL AB. Wrote the paper: FL AB. 25. Ewald B, Sampath D, Plunkett W (2008) Nucleoside analogs: molecular mechanisms signalling cell death. Oncogene 27: 6522–6537. 26. Lee VM, Andrews PW (1986) Differentiation of NTERA-2 clonal human embryonal carcinoma cells into neurons involves the induction of all three neurofilament proteins. J Neurosci 6: 514–521. 27. Sheridan KM, Maltese WA (1998) Expression of Rab3A GTPase and other synaptic proteins is induced in differentiated NT2N neurons. J Mol Neurosci 10: 121–128. 28. Przyborski SA, Christie VB, Hayman MW, Stewart R, Horrocks GM (2004) Human embryonal carcinoma stem cells: models of embryonic development in humans. Stem Cells Dev 13: 400–408. 29. Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, et al. (2006) Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res 66: 10664–10670. 30. Reynolds PA, Sigaroudinia M, Zardo G, Wilson MB, Benton GM, et al. (2006) Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethy- lation in human mammary epithelial cells. J Biol Chem 281: 24790–24802. 31. Xi S, Zhu H, Xu H, Schmidtmann A, Geiman TM, et al. (2007) Lsh controls Hox gene silencing during development. Proc Natl Acad Sci USA 104: 14366–143671. 32. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, et al. (2004) Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2: 62–72. 33. Fujita J, Crane AM, Souza MK, Dejosez M, Kyba M, et al. (2008) Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell 2: 595–601. 34. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12: 440–450. 35. Lamkanfi M, Kanneganti TD (2010) Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol 42: 21–24. 36. Gerrard L, Zhao D, Clark AJ, Cui W (2005) Stably transfected human embryonic stem cell clones express OCT4-specific green fluorescent protein and maintain self-renewal and pluripotency. Stem Cells 23: 124–133. 37. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, et al. (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modifi- cation by lactacystin. Science 268: 726–731. 38. Plimack ER, Kantarjian HM, Issa JP (2007) Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 48: 1472–1481. 39. D’Sa-Eipper C, Roth KA (2000) Caspase regulation of neuronal progenitor cell apoptosis. Dev Neurosci 22: 116–124. 40. Tamm I, Wagner M, Schmelz K (2005) Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol 84: 47–53. 41. Jiemjit A, Fandy TE, Carraway H, Baily KA, Baylin S, et al. (2008) p21(WAF1/ CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27: 3615–3623. 42. Yoshida K, Miki Y, Kufe D (2002) Activation of SAPK/JNK signalling by protein kinase Cdelta in response to DNA damage. J Biol Chem 277: 48372–48378. 43. Luisi-DeLuca C, Mitchell T, Spriggs D, Kufe DW (1984) Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcyto- sine. J Clin Invest 74: 821–827. 44. Meyer M, Ru¨bsamen D, Slany R, Illmer T, Stabla K, et al. (2009) Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One 4: e7768. 45. Curtin JC, Dragnev KH, Sekula D, Christie AJ, Dmitrovsky E, et al. (2001) Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene 20: 2559–2569. 46. Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, et al. (2008) Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms. Mol Cell 32: 503–518. 47. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, et al. (2008) EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency. Mol Cell 32: 491–502. PLoS ONE | www.plosone.org 14 May 2010 | Volume 5 | Issue 5 | e10726